{
    "clinical_study": {
        "@rank": "168106", 
        "arm_group": {
            "arm_group_label": "Grape Seed Extract and Vitamin D", 
            "arm_group_type": "Experimental", 
            "description": "All patients will take Grape Seed Extract from Day 1 to Day 21. All patients will take Grape Seed Extract and Vitamin D together from Day 22 until Day 64.  For all patients on the study, patients will take Vitamin D once a day at a dose of 4000IU."
        }, 
        "brief_summary": {
            "textblock": "This study is for subjects with solid cancers (gastrointestinal, lung, breast, prostate,\n      lymphoma or cancer of the lymph nodes).  The overall goal of this study is to identify\n      plant-derived phytochemicals that can safely reduce systemic inflammation (inflammation\n      throughout the entire body) in subjects with advanced cancer."
        }, 
        "brief_title": "Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Cancers", 
        "detailed_description": {
            "textblock": "This study will look at oligomeric procyanidin complex (OPC) and vitamin D3.  OPC is the\n      major part of Grape Seed Extract (GSE). Researchers are in looking at the combination of GSE\n      and vitamin D in subjects with solid cancers (gastrointestinal, lung, breast, prostate,\n      lymphoma or cancer of the lymph nodes).  Researchers will examine the safety of the GSE and\n      vitamin D when GSE is given at different doses. Researchers will also look at the effects of\n      GSE and vitamin D on your quality of life and your body. In particular, they will look at\n      differences in biomarkers in your blood and urine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects must have a histological diagnosis of cancer\n\n          -  Subjects must be 21 or more years of age\n\n          -  Subjects must have metastatic or locally advanced, unresectable cancer. Cancer must\n             be \"active\" (i.e. demonstrable by physical examination, blood tests, or\n             radiographical procedures).\n\n          -  Subjects may not initiate a new form of cancer therapy, non-steroidal or steroid\n             anti-inflammatory agents, or antibiotics during the study period or for 4 weeks prior\n             to the start of study agents.\n\n          -  Subjects must be able to give written consent to the study.\n\n          -  Subjects must have adequate hematologic, renal, and hepatic function at baseline, as\n             follows:\n\n          -  Hematology parameters: ANC >1500/mcL, platelets > 100,000/mcL, Hgb >8.0gm/dL\n\n          -  Renal Function: Creatinine <1.8mg/mL\n\n          -  Liver Function: Total bilirubin \u2264ULN, AST and ALT <1.5xULN, Alk phosphatase <2.5xULN\n\n          -  Subjects must have normal serum phosphate and serum calcium levels:\n\n          -  Serum Phosphate > 2.3 and < 4.8 mg/dL\n\n          -  Serum Calcium > 8.5 and < 10.5\n\n          -  Subjects may be receiving anti-cancer treatment, but this treatment should be have\n             been instituted at least 4 weeks prior to enrollment, and may not change during the\n             study period.\n\n        Exclusion Criteria:\n\n          -  Uncontrolled cancer requiring the institution of new anti-cancer therapy during the\n             study period.\n\n          -  Presence of any severe or uncontrolled concurrent medical condition which, in the\n             opinion of the investigator, would increase the risk of serious toxicity from the\n             study drugs.\n\n          -  Any uncontrolled systemic inflammatory disease or infection requiring antibiotics,\n             non-steroidal, or steroidal anti-inflammatory agents.\n\n          -  Initiation of strong antioxidant supplements during treatment, or ongoing use of\n             supplements containing concentrated plant-derived polyphenols (pine bark, grape seed,\n             green tea, milk thistle extracts; resveratrol; ellagic acid)\n\n          -  Pregnancy or breast feeding\n\n          -  Any history of allergies to grapes or grape seed.\n\n          -  Current treatment with lenalidomide, thalidomide, imipquimod, interferon, cytokines\n             (G-CSF, GM-CSF, IL-1R\u03b1), TNF\u03b1 antagonists, or Lithium.\n\n          -  History of sarcoidosis\n\n          -  History of hypercalcemia\n\n          -  Use of any non-protocol vitamin D supplementation.\n\n          -  Uncontrolled hypertension\n\n          -  Current treatment with warfarin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01820299", 
            "org_study_id": "101839"
        }, 
        "intervention": [
            {
                "arm_group_label": "Grape Seed Extract and Vitamin D", 
                "description": "All patients enrolled to the study will take Grape Seed Extract alone for 21 days.", 
                "intervention_name": "Grape Seed Extract", 
                "intervention_type": "Drug", 
                "other_name": "GSE"
            }, 
            {
                "arm_group_label": "Grape Seed Extract and Vitamin D", 
                "description": "From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together.  Patients will take Vitamin D once at a day at 4000 IU.", 
                "intervention_name": "Vitamin D", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Anti-Inflammatory Agents", 
                "Vitamin D", 
                "Ergocalciferols", 
                "Vitamins", 
                "Grape Seed Extract"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 19, 2014", 
        "location": {
            "contact": {
                "email": "lillym@musc.edu", 
                "last_name": "Michael Lilly, MD", 
                "phone": "843-792-4271"
            }, 
            "contact_backup": {
                "email": "brisend@musc.edu", 
                "last_name": "Alan Brisendine, CCRP", 
                "phone": "843-792-9007"
            }, 
            "facility": {
                "address": {
                    "city": "Charleston", 
                    "country": "United States", 
                    "state": "South Carolina", 
                    "zip": "29412"
                }, 
                "name": "Medical University of South Carolina"
            }, 
            "investigator": [
                {
                    "last_name": "Michael Lilly, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Carolyn Britten, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Steve Chin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Harry Drabkin, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sebastiano Gattoni-Celli, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Andrew Kraft, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "David Marshall, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Keisuke Shirai, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Melanie Thomas, MD", 
                    "role": "Sub-Investigator"
                }, 
                {
                    "last_name": "Sara Giordano, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I Assay-guided Trial of Anti-inflammatory Phytochemicals in Patients With Advanced Cancer", 
        "other_outcome": [
            {
                "description": "Other markers that will be measured will include serum CRP, albumin, AGEs (advanced glycation end products), rAGE (soluble receptor for AGEs), 25-OH-vitamin D3, and urine for oxidative damage DNA biomarkers (urinary 8-oxoGua and 8-oxodG). Correlations between dose and change in these parameters from before to 21, 63 days after start of GSE dosing will be described.", 
                "measure": "Measurement of Other Inflammatory Markers", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Serial QOL assessments will be made by the FACT series of QOL questionnaires", 
                "measure": "Quality of Life Questionnaires", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The ability of a fixed dose of vitamin D3 (4000 IU daily) to further suppress IL-6 levels in subjects on GSE treatment will be evaluated.", 
                "measure": "Effect of Vitamin D3 on Anti-Inflammatory Effects of GSE", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }
        ], 
        "overall_contact": {
            "email": "lillym@musc.edu", 
            "last_name": "Michael Lilly, MD", 
            "phone": "843-792-4271"
        }, 
        "overall_contact_backup": {
            "email": "brisend@musc.edu", 
            "last_name": "Alan Brisendine, CCRP", 
            "phone": "843-792-9007"
        }, 
        "overall_official": {
            "affiliation": "Medical University of South Carolina", 
            "last_name": "Michael Lilly, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Decisions to escalate or expand a dose level will be based only on the GSE-only treatment period (day 1-21). To be evaluable for toxicity, a patient must receive at least 3 weeks of GSE treatment, or have experienced dose-limiting toxicity (DLT). All patients enrolled are to be fully followed for toxicity, but any patients who are not evaluable for toxicity will be replaced.", 
            "measure": "Maximally-tolerated dose of Grape Seed Extract in Patients with Solid Tumors", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01820299"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma IL-6 levels before and after 21 days and 63 days of GSE treatment will be quantified to estimate the dose response relationship between GSE dose and reduction in inflammation.", 
            "measure": "IL6 Response", 
            "safety_issue": "Yes", 
            "time_frame": "2 years"
        }, 
        "source": "Medical University of South Carolina", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medical University of South Carolina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}